Breaking World Pharma News

Transplant drug could boost the power of brain tumor treatments

Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. New research suggests that the same drug could help brain tumor patients by boosting the effect of new immune-based therapies.

Read more...

New research outlines promising therapies for small cell lung cancer

Two recently published studies by a research team at University Hospitals (UH) Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.

Read more...

Novo Nordisk establishes new obesity research unit in Seattle

Novo NordiskNovo Nordisk has announced that the company will establish a new obesity research unit in Seattle, Washington, in the US. The new unit is a result of Novo Nordisk's increasing focus on treatment of obesity. Its main task will be to identify novel approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets.

Read more...

Discrepancies in access to new cancer drugs revealed

Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain. Researchers say the results demonstrate the need for better collaboration between doctors and health authorities on an international scale, to ensure patients have access to the best treatments.

Read more...

MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory

AstraZenecaAstraZeneca today announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK.

Read more...

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

Boehringer IngelheimBoehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, have announced an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine, in early clinical development for the treatment of lung cancer.

Read more...

Stanford researchers create 'evolved' protein that may stop cancer from spreading

A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body. This process, known as metastasis, can cause cancer to spread with deadly effect.

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]